Results 81 to 90 of about 2,997 (148)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD

, 2013
Anthony D'UrzoDepartment of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaAbstract: Progressive airflow limitation is a hallmark feature of chronic obstructive pulmonary disease (COPD) that ultimately leads to ...
D’Urzo A
core  

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan

, 2015
Nobuyuki Horita, Takeshi Kaneko Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan Abstract: Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device ...
Horita N, Kaneko T
core  

Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo

, 2020
Background and Purpose: Combining inhaled corticosteroids (ICSs), long-acting β2-adrenoceptor agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) is recommended to treat severe forms of asthma and chronic obstructive pulmonary disease (COPD).
Facciolo F., Matera M. G., Calzetta L., Rogliani P., Cazzola M., Page C.   +5 more
core   +1 more source

The effect of glycopyrronium bromide on nocturnal clozapineinduced sialorrhoea in psychiatric patients [PDF]

, 2015
OBJECTIVE: To determine the effect of oral glycopyrronium bromide in comparison with placebo on the severity of complaints of nocturnal sialorrhoea in psychiatric patients treated with clozapine and also in a subset of patients using a double dose of ...
Wilting, I., Sub Clinical Pharmacy, Pharmacoepi, Colen-De Koning, J. C A, Van Haelst, I. M M, Cahn, W., Cahn, W, Schulte, PFJ, Schulte, P. F J, Egberts, A. C G, Wilting, I, Egberts, ACG, Man, W. H., Heerdink, E.R., Man, WH, Pharmacoepidemiology and Clinical Pharmacology, Doodeman, H.J., Doodeman, H. J., Colen-de Koning, Jantien, Heerdink, E. R., van Haelst, I.M.M.   +19 more
core   +1 more source

Implementation of quality by design and green chemistry principles to validate the stability indicating method on UHPLC for the simultaneous quantification of Glycopyrronium, Fluticasone, Vilanterol in inhaled formulation

Green Analytical Chemistry
The combination of Glycopyrronium, Fluticasone, and Vilanterol is utilized to manage chronic obstructive pulmonary disease (COPD) and mitigate asthma symptoms.
Anitha L, Durga Prasad Beda
doaj   +1 more source

Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study

, 2019
Alan Kaplan,1 Kenneth R Chapman,2 Syed M Anees,3 Irvin Mayers,4 Driss Rochdi,5 Michel Djandji,5 David Préfontaine,5 Andrew McIvor6 1Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada; 2Division of Respiratory ...
Préfontaine D, Kaplan A, Anees SM, Djandji M, Rochdi D, Chapman KR, Mayers I, McIvor A   +7 more
core  

Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi

, 2015
Preclinical studies suggested that aclidinium and glycopyrronium might have a faster onset of action than tiotropium. In this study we assessed the onset of action of aclidinium and glycopyrronium versus tiotropium, all administered at the approved ...
Calzetta, L, Roberto Lipsi, Cazzola, M, ROGLIANI, PAOLA, Segreti, A, Luigino Calzetta, Josuel Ora, Paola Rogliani, CAZZOLA, MARIO, Andrea Segreti, SEGRETI, ANDREA, CALZETTA , LUIGINO, Mario Cazzola, Rogliani, P, Matera, Mg, Ora, J, Maria Gabriella Matera, Lipsi, R   +17 more
core   +1 more source

Coexisting Heart Failure and Chronic Obstructive Pulmonary Disease: Report of Two Cases Treated with Indacaterol/Glycopyrronium

, 2018
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, and it is associated with a high economic burden. Heart failure shares some general symptoms with COPD; thus, diagnosing COPD is difficult in subjects ...
Crescenzio Bentivenga, Daniela Degli Esposti, Landolfo, Matteo, Gianluigi Magri, Borghi, Claudio, Rinaldo Miceli, Claudio Borghi, RICCI IAMINO, ILARIA, Matteo Landolfo, BENTIVENGA, CRESCENZIO, Spinardi, Luca, MAGRI, GIANLUIGI, Degli Esposti, Daniela, Luca Spinardi, Cosentino, Eugenio Roberto, MICELI, RINALDO, Ilaria Ricci Iamino, Eugenio Roberto Cosentino   +17 more
core   +1 more source

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis

International Journal of COPD, 2015
Afisi Segun Ismaila,1,2 Eline L Huisman,3 Yogesh Suresh Punekar,4 Andreas Karabis31Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA; 2Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; 3Real ...
Ismaila AS, Huisman EL, Punekar YS, Karabis A   +3 more
doaj  

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK) : a randomised, double-blind, parallel-group study

, 2013
Background: We evaluated the effect of dual, longacting inhaled bronchodilator treatment on exacerbations in patients with severe and very severe chronic obstructive pulmonary disease (COPD).Methods: In this parallel-group study, 2224 patients (aged ≥40 ...
Niewoehner, Dennis E., Chen, Hungta, Banerji, Donald, Wedzicha, Jadwiga A., Decramer, Marc, Ficker, Joachim H., D'Andrea, Peter, Fowler Taylor, Angel, Sandström, Thomas,, Arrasate, Christie   +9 more
core   +1 more source